What does this research mean for the field?

Perioperative administration of propranolol is operationally feasible and demonstrates an acceptable safety profile in patients undergoing robotic-assisted laparoscopic prostatectomy for intermediate- or high-risk prostate cancer. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To determine the feasibility and safety of administering perioperative propranolol to reduce prostate cancer recurrence in patients undergoing robotic-assisted laparoscopic prostatectomy for intermediate- or high-risk disease.

August 29, 2026BJUI CompassOpen Access

Perioperative propranolol during robotic‐assisted radical prostatectomy: A randomised, double‐blind, placebo‐controlled, pilot trial (PeP‐RALP)

View Full Paper

Ask AI

Bookmark

Authors

SSShivanthe SivanesanOslo University Hospital HRH. RambergOslo University Hospital TKThomas KristiansenOslo University Hospital

Discussion

Member takes

Implication

Randomized double-blind trial demonstrates the feasibility and safety of perioperative propranolol in men undergoing radical prostatectomy, indicating potential for larger oncological efficacy trials.

Key Points

To determine the feasibility and safety of administering perioperative propranolol to reduce prostate cancer recurrence in patients undergoing robotic-assisted laparoscopic prostatectomy for intermediate- or high-risk disease.
Single-centre, randomised, double-blind, placebo-controlled, phase 2 pilot trial enrolling 40 treatment-naïve men aged 40–80 years with intermediate- or high-risk prostate cancer scheduled for robotic-assisted laparoscopic prostatectomy.
Participants were randomised 1:1 to receive propranolol or placebo for approximately 3 weeks (around 1 week before surgery and 2 weeks after surgery), with serial blood sampling and twice-daily blood pressure monitoring.
Recruitment achieved 40 randomised patients (82% of fully screened and 36% of prescreened candidates); pre-surgery adherence was 98% in both arms, though post-surgery adherence decreased in the propranolol arm.
No Common Terminology Criteria for Adverse Events grade ≥3 adverse events were attributed to propranolol, and no surgical procedures were delayed.
Metanephrine increased intraoperatively in both arms, and mean preoperative prostate-specific antigen decreased more with propranolol than placebo in exploratory evaluations.

Cite This Study

Sivanesan et al. (2026) studied this question.

synapsesocial.com/papers/6a9299c88e5d7d1fc0c11fbe https://doi.org/10.1002/bco2.70267

View Full Paper

Ask AI

Bookmark

Perioperative propranolol during robotic‐assisted radical prostatectomy: A randomised, double‐blind, placebo‐controlled, pilot trial (PeP‐RALP)

Discussion

Member takes

Implication

Key Points

Cite This Study

Perioperative propranolol during robotic‐assisted radical prostatectomy: A randomised, double‐blind, placebo‐controlled, pilot trial (PeP‐RALP)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider